“More than 7,000 diseases”, “More than 300 million patients worldwide”, “50% of patients are children”… On February 27, the first anniversary of the launch of the “Jingdong Pharmacy Rare Disease Care Center” and JD Health At the “Rare Disease Whole Ecosystem Service Strategy Conference”, with the release of the “2022 China Rare Disease Industry Trend Observation Report” by Frost & Sullivan and the Pain Challenge Foundation, behind a set of numbers, it is reflected that it is easy to be misunderstood. Current status of neglected rare disease groups. The report also shows that 70% of medical workers believe that they do not understand rare diseases, and more than 80% of patients in some provinces need to go to major cities in other provinces to obtain treatment and purchase related drugs.
On the same day, JD Health announced that after more than a year of accumulation, it will continue to work with all parties in the industry chain. , comprehensively deepen and jointly build the whole ecological service system of “medicine + medicine + service + payment” for rare diseases, create a whole ecological service platform for rare diseases, and provide the industry and users with one-stop service for the listing of domestically approved drugs for rare diseases; further Focus on the availability of drugs, payment, and services for rare diseases, and provide more comprehensive and powerful help to the rare disease community.
According to statistics, since the “Jingdong Health Rare Disease Care Plan” was launched on the eve of the International Rare Disease Day in 2021, a total of more than 24,000 rare disease patients have purchased rare disease drugs and obtained them from JD Health. For corresponding medication services, nearly 70% of them continue to obtain rare disease-related health management services through the “Jingdong Pharmacy Rare Disease Care Center”.
As we all know, the research and development of rare disease drugs is difficult and the cycle is long, and it has been difficult to meet the clinical needs of patients. Drug time, cost, etc. face varying degrees of challenges. Therefore, drug accessibility has become one of the most urgent issues to be addressed in the prevention and treatment of rare diseases.
Not only that, compared with general medicines, most rare disease medicines have special requirements for storage, transportation and distribution, and require special system support such as cold chain. In addition, the approval and marketing process of drugs for rare diseases is also more complicated than other drugs, which also causes inconvenience for patients to purchase drugs to a certain extent.
In this context, in order to help solve the problem of drug purchase for rare disease patients, since 2021, JD Pharmacy has effectively promoted more rare disease drugs by giving full play to its superior pharmaceutical supply chain capabilities. The realization of undifferentiated supply across the country, and in the process, has accumulated and precipitated the full-chain supporting service capabilities for new and special drugs for rare diseases.
Among them, Jingdong Pharmacy has actively promoted the approval of drugs for rare diseases in China through cooperation with many domestic and foreign rare disease drug companies. Fast time to market.
JD Health also continued to upgrade its “self-operated cold chain” drug service model, providing online and offline integrated supply chain solutions from warehousing to distribution. As of the end of December 2021, the number of cities covered by the “self-operated cold chain” capability of JD Pharmacy has exceeded 200, and patients in these areas can obtain cold chain rare disease drugs as soon as possible.
In addition, JD Health and its ecological partners have innovated a multi-party co-payment model. In addition to establishing a “Rare Disease Care Fund” with the Pain Challenge Foundation to directly provide charitable assistance for rare disease patients, JD Health has also joined forces with JD.com. Many brand merchants have launched “Love Dongdong”, innovating the public welfare assistance model, reducing the payment pressure and providing one-stop services for more patients. Up to now, JD Health Rare Disease Care Fund has received assistance applications from more than 800 patients, including the third batch of projects in progress, and completed 3 patient assistance audits, assisted 123 person-times in total, and directly allocated more than 1.1 million yuan; ” Just three months after the launch of the “Love Dongdong” project, more than 2,000 stores have settled in, and 1.3 million “Love” products have been sold. In 2022, in order to further meet the “last mile” needs of rare disease patients, JD Health will continue to improve its service capabilities for rare disease patients. The “Jingdong Pharmacy Rare Disease Care Center” has been fully upgraded and can provide rare disease patients with a series of services including self-testing and early warning, doctor-patient interaction, digital and intelligent diagnosis, precise medication, intelligent nursing, and follow-up plans.
Secondly, cooperate with the Illness Challenge Foundation and patient organizations of multiple diseases to establish a “Single Disease Patient Care Service Group”, which is aimed at JD Health’s rare disease drug purchasers and rare disease care fund application users , to provide more comprehensive whole-course rehabilitation and care services.
In addition, JD Health stated that it will continue to cooperate with pharmaceutical companies, foundations and other partners to continuously improve its medical and health service capabilities with the goal of accelerating diagnosis, and gradually launch and improve the “Famous Doctors on the Cloud for Rare Diseases”. New service functions such as Rare Disease Cloud Classroom and Rare Disease Genetic Testing. JD Health will also build a training area for rare disease doctors to improve more grassroots doctors’ awareness of rare diseases, shorten the diagnosis time of rare diseases as much as possible, and help rare disease patients enter the treatment and recovery period more quickly.
Correspondent Xiu Ting